Supernus Pharmaceuticals (SUPN) Earns Hold Rating from Piper Jaffray Companies

Share on StockTwits

Piper Jaffray Companies reiterated their hold rating on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a research report released on Thursday. They currently have a $44.00 price target on the specialty pharmaceutical company’s stock. Piper Jaffray Companies also issued estimates for Supernus Pharmaceuticals’ Q3 2018 earnings at $0.49 EPS, Q4 2018 earnings at $0.48 EPS, Q1 2019 earnings at $0.52 EPS, Q2 2019 earnings at $0.63 EPS, Q3 2019 earnings at $0.63 EPS, Q4 2019 earnings at $0.70 EPS, FY2019 earnings at $2.07 EPS and FY2020 earnings at $3.33 EPS.

Several other analysts have also weighed in on SUPN. BidaskClub upgraded shares of Supernus Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Friday, June 22nd. ValuEngine lowered shares of Supernus Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Friday, June 8th. Cantor Fitzgerald set a $56.00 price objective on shares of Supernus Pharmaceuticals and gave the company a buy rating in a research note on Wednesday. Stifel Nicolaus boosted their price target on shares of Supernus Pharmaceuticals from $50.00 to $60.00 and gave the company a buy rating in a research note on Friday, May 25th. Finally, Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a hold rating to a strong sell rating in a research note on Saturday, May 5th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. Supernus Pharmaceuticals presently has an average rating of Buy and an average price target of $54.09.

Shares of NASDAQ:SUPN traded down $1.95 during mid-day trading on Thursday, hitting $46.15. The company had a trading volume of 1,498,373 shares, compared to its average volume of 732,104. The firm has a market capitalization of $2.49 billion, a P/E ratio of 36.63 and a beta of 0.97. The company has a quick ratio of 4.74, a current ratio of 2.74 and a debt-to-equity ratio of 0.82. Supernus Pharmaceuticals has a one year low of $33.30 and a one year high of $61.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.14. The company had revenue of $99.54 million during the quarter, compared to analyst estimates of $101.01 million. Supernus Pharmaceuticals had a net margin of 24.17% and a return on equity of 30.57%. analysts anticipate that Supernus Pharmaceuticals will post 1.91 EPS for the current fiscal year.

In other news, CFO Gregory S. Patrick sold 35,000 shares of the company’s stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $56.63, for a total value of $1,982,050.00. Following the completion of the sale, the chief financial officer now owns 75,975 shares in the company, valued at approximately $4,302,464.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 7,205 shares of the company’s stock in a transaction on Thursday, June 21st. The stock was sold at an average price of $60.00, for a total transaction of $432,300.00. Following the completion of the sale, the vice president now owns 14,705 shares of the company’s stock, valued at approximately $882,300. The disclosure for this sale can be found here. Insiders have sold a total of 117,868 shares of company stock valued at $6,600,620 in the last 90 days. 6.20% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Stephens Investment Management Group LLC grew its stake in shares of Supernus Pharmaceuticals by 2.5% in the 2nd quarter. Stephens Investment Management Group LLC now owns 187,230 shares of the specialty pharmaceutical company’s stock worth $10,925,000 after acquiring an additional 4,630 shares in the last quarter. NumerixS Investment Technologies Inc bought a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth $204,000. Federated Investors Inc. PA grew its stake in shares of Supernus Pharmaceuticals by 447.4% in the 2nd quarter. Federated Investors Inc. PA now owns 168,735 shares of the specialty pharmaceutical company’s stock worth $10,099,000 after acquiring an additional 137,909 shares in the last quarter. FMR LLC grew its stake in shares of Supernus Pharmaceuticals by 1,909.6% in the 2nd quarter. FMR LLC now owns 941,300 shares of the specialty pharmaceutical company’s stock worth $56,337,000 after acquiring an additional 894,459 shares in the last quarter. Finally, DE Burlo Group Inc. bought a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth $2,184,000. Hedge funds and other institutional investors own 98.01% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Further Reading: Trading Strategy

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply